+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Antineoplastic Agents Market by Product Type (Cytotoxic Agents, Hormonal Agents, Immunomodulators), Route Of Administration (Intravenous, Oral, Subcutaneous), Indication, Distribution Channel - Global Forecast 2025-2030- Product Image
Antineoplastic Agents Market by Product Type (Cytotoxic Agents, Hormonal Agents, Immunomodulators), Route Of Administration (Intravenous, Oral, Subcutaneous), Indication, Distribution Channel - Global Forecast 2025-2030- Product Image
Sale

Antineoplastic Agents Market by Product Type (Cytotoxic Agents, Hormonal Agents, Immunomodulators), Route Of Administration (Intravenous, Oral, Subcutaneous), Indication, Distribution Channel - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 199 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 5887460
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The antineoplastic agents market is experiencing pivotal transformation, driven by innovation, evolving regulatory pathways, and changing stakeholder requirements across the oncology care continuum. With increasing demand for more targeted and patient-centric therapies, industry leaders are focused on addressing diverse needs spanning traditional and next-generation cancer treatments.

Market Snapshot: Antineoplastic Agents Market Overview

The Antineoplastic Agents Market grew from USD 143.82 billion in 2024 to USD 158.96 billion in 2025. It is expected to continue growing at a CAGR of 10.44%, reaching USD 260.98 billion by 2030. This robust expansion reflects rapid adoption of advanced therapies, expansion of global oncology care infrastructure, and shifting treatment paradigms guiding decisions for providers, payers, and manufacturers.

Scope & Segmentation

This report on the antineoplastic agents market provides comprehensive coverage across multiple segmentations, ensuring actionable intelligence for stakeholders:

  • Product Types: Includes cytotoxic agents (alkylating agents, antimetabolites, mitotic inhibitors), hormonal agents (anti-estrogens, aromatase inhibitors, LHRH agonists), immunomodulators, monoclonal antibodies (such as anti-CD20, anti-HER2, anti-PD-1/PD-L1), and tyrosine kinase inhibitors (including BCR-ABL inhibitors, EGFR inhibitors, VEGF inhibitors).
  • Routes of Administration: Covers intravenous, oral, and subcutaneous delivery, each critical for tailoring patient experience and treatment settings.
  • Indications: Analyzes use in hematological cancers (leukemia, lymphoma, multiple myeloma) and solid tumors (breast, colorectal, non-small cell lung cancer, small cell lung cancer).
  • Distribution Channels: Encompasses hospital pharmacy, online pharmacy, and retail pharmacy, highlighting evolving access points for oncology care.
  • Regional Markets: Evaluates dynamics and opportunities within Americas (United States, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (including United Kingdom, Germany, France, and more), and Asia-Pacific (China, India, Japan, Australia, among others).
  • Key Companies: Examines strategies and portfolios of Roche Holding AG, Merck & Co., Inc., Johnson & Johnson, Bristol-Myers Squibb Company, Novartis AG, Pfizer Inc., AstraZeneca PLC, AbbVie Inc., Amgen Inc., and Eli Lilly and Company.

Key Takeaways for Senior Decision Makers

  • Antineoplastic agents increasingly form the core of both established and innovative oncology treatment protocols, integrating traditional compounds with targeted and immune-based therapies.
  • Personalization in treatment is advancing rapidly through biomarker use and precision diagnostic approaches, shifting the paradigm from standardized regimens to tailored therapies that address individual patient profiles.
  • New regulatory frameworks are enabling faster approval and broader access to breakthrough cancer medicines, encouraging closer collaboration between manufacturers and regulatory bodies to maintain high safety and efficacy standards.
  • Market segmentation highlights emerging opportunities in patient-centric administration routes, especially in oral and subcutaneous formulations, which enhance adherence and streamline clinical workflows.
  • Regional market differences require strategic agility as regulatory maturity, infrastructure capacity, and price sensitivity vary widely—especially in emerging markets where local partnerships and capacity building are crucial.
  • Consolidation and portfolio diversification among leading pharma and biotech firms drive competitive positioning and foster innovation, affecting the speed and scale of therapeutic rollout worldwide.

Tariff Impact: Strategic Responses to US Policy Shifts

The imposition of new United States tariffs in 2025 has affected global supply chains by increasing raw material and active pharmaceutical ingredient costs. In response, manufacturers are reevaluating sourcing, pursuing supplier diversity, and developing dual sourcing strategies to ensure consistent supply. Downstream, these shifts impact hospital and pharmacy budgets, prompting value-based negotiations and a collaborative approach among providers, payers, and industry stakeholders to sustain patient access and affordability.

Methodology & Data Sources

Insights are derived from a balanced methodology combining primary interviews with key opinion leaders in oncology and supply chain management, with extensive secondary research from regulatory filings, financial reports, and peer-reviewed literature. Data triangulation and expert validation ensure robust findings, translating into actionable intelligence.

Why This Report Matters

  • Deliver actionable insights critical for shaping R&D, commercial, and market entry strategies in a rapidly evolving oncology landscape.
  • Support strategic planning by detailing core market drivers, technology trends, and competitive moves, reducing uncertainty for investment and partnership decisions.
  • Help senior leaders anticipate regulatory and market disruptions, enabling proactive risk management and sustained growth.

Conclusion

The antineoplastic agents market is defined by continual innovation and the pursuit of more effective, patient-focused cancer care. Leaders who remain agile, embrace emerging technologies, and align with evolving global trends will secure long-term market relevance and impact.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Advances in personalized oncology therapies driven by next-generation sequencing identifying rare mutations
5.2. Increasing adoption of bispecific antibodies for solid tumors demonstrating enhanced tumor cell engagement
5.3. Rising integration of CAR-T and CAR-NK cell therapies in earlier lines of treatment to improve patient outcomes
5.4. Growing pipeline of antibody-drug conjugates targeting novel tumor-specific antigens for precision treatment
5.5. Expansion of oral oncolytic agents offering improved patient convenience and adherence in metastatic settings
5.6. Regulatory approvals of tumor-agnostic drugs targeting genetic biomarkers across multiple cancer types
5.7. Development of next-generation KRAS and EGFR inhibitors to overcome resistance in lung cancer patients
5.8. Emergence of microbiome-modulating adjuvants to enhance efficacy of immune checkpoint inhibitors
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Antineoplastic Agents Market, by Product Type
8.1. Introduction
8.2. Cytotoxic Agents
8.2.1. Alkylating Agents
8.2.2. Antimetabolites
8.2.3. Mitotic Inhibitors
8.3. Hormonal Agents
8.3.1. Anti Estrogens
8.3.2. Aromatase Inhibitors
8.3.3. Lhrh Agonists
8.4. Immunomodulators
8.5. Monoclonal Antibodies
8.5.1. Anti Cd20 Antibodies
8.5.2. Anti Her2 Antibodies
8.5.3. Anti Pd-1/Pd-L1 Inhibitors
8.6. Tyrosine Kinase Inhibitors
8.6.1. Bcr-Abl Inhibitors
8.6.2. Egfr Inhibitors
8.6.3. Vegf Inhibitors
9. Antineoplastic Agents Market, by Route Of Administration
9.1. Introduction
9.2. Intravenous
9.3. Oral
9.4. Subcutaneous
10. Antineoplastic Agents Market, by Indication
10.1. Introduction
10.2. Hematological Cancer
10.2.1. Leukemia
10.2.2. Lymphoma
10.2.3. Multiple Myeloma
10.3. Solid Tumor
10.3.1. Breast Cancer
10.3.2. Colorectal Cancer
10.3.3. Lung Cancer
10.3.3.1. Non Small Cell Lung Cancer
10.3.3.2. Small Cell Lung Cancer
11. Antineoplastic Agents Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacy
11.3. Online Pharmacy
11.4. Retail Pharmacy
12. Americas Antineoplastic Agents Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Antineoplastic Agents Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Antineoplastic Agents Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. Roche Holding AG
15.3.2. Merck & Co., Inc.
15.3.3. Johnson & Johnson
15.3.4. Bristol-Myers Squibb Company
15.3.5. Novartis AG
15.3.6. Pfizer Inc.
15.3.7. AstraZeneca PLC
15.3.8. AbbVie Inc.
15.3.9. Amgen Inc.
15.3.10. Eli Lilly and Company
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. ANTINEOPLASTIC AGENTS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS ANTINEOPLASTIC AGENTS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 14. AMERICAS ANTINEOPLASTIC AGENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES ANTINEOPLASTIC AGENTS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 16. UNITED STATES ANTINEOPLASTIC AGENTS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA ANTINEOPLASTIC AGENTS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ANTINEOPLASTIC AGENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC ANTINEOPLASTIC AGENTS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC ANTINEOPLASTIC AGENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ANTINEOPLASTIC AGENTS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 22. ANTINEOPLASTIC AGENTS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 23. ANTINEOPLASTIC AGENTS MARKET: RESEARCHAI
FIGURE 24. ANTINEOPLASTIC AGENTS MARKET: RESEARCHSTATISTICS
FIGURE 25. ANTINEOPLASTIC AGENTS MARKET: RESEARCHCONTACTS
FIGURE 26. ANTINEOPLASTIC AGENTS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. ANTINEOPLASTIC AGENTS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY CYTOTOXIC AGENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY CYTOTOXIC AGENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY ANTIMETABOLITES, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY ANTIMETABOLITES, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY MITOTIC INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY MITOTIC INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY CYTOTOXIC AGENTS, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY CYTOTOXIC AGENTS, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY HORMONAL AGENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY HORMONAL AGENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY ANTI ESTROGENS, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY ANTI ESTROGENS, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY AROMATASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY AROMATASE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY LHRH AGONISTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY LHRH AGONISTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY HORMONAL AGENTS, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY HORMONAL AGENTS, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY IMMUNOMODULATORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY IMMUNOMODULATORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY ANTI CD20 ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY ANTI CD20 ANTIBODIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY ANTI HER2 ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY ANTI HER2 ANTIBODIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY ANTI PD-1/PD-L1 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY ANTI PD-1/PD-L1 INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY BCR-ABL INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY BCR-ABL INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY EGFR INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY EGFR INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY VEGF INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY VEGF INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY HEMATOLOGICAL CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY HEMATOLOGICAL CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY LEUKEMIA, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY LYMPHOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY MULTIPLE MYELOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY MULTIPLE MYELOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY HEMATOLOGICAL CANCER, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY HEMATOLOGICAL CANCER, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY SOLID TUMOR, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY SOLID TUMOR, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY BREAST CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY LUNG CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY SMALL CELL LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY SMALL CELL LUNG CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY SOLID TUMOR, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY SOLID TUMOR, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 91. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 92. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 93. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 94. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 95. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 96. GLOBAL ANTINEOPLASTIC AGENTS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 97. AMERICAS ANTINEOPLASTIC AGENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 98. AMERICAS ANTINEOPLASTIC AGENTS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 99. AMERICAS ANTINEOPLASTIC AGENTS MARKET SIZE, BY CYTOTOXIC AGENTS, 2018-2024 (USD MILLION)
TABLE 100. AMERICAS ANTINEOPLASTIC AGENTS MARKET SIZE, BY CYTOTOXIC AGENTS, 2025-2030 (USD MILLION)
TABLE 101. AMERICAS ANTINEOPLASTIC AGENTS MARKET SIZE, BY HORMONAL AGENTS, 2018-2024 (USD MILLION)
TABLE 102. AMERICAS ANTINEOPLASTIC AGENTS MARKET SIZE, BY HORMONAL AGENTS, 2025-2030 (USD MILLION)
TABLE 103. AMERICAS ANTINEOPLASTIC AGENTS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 104. AMERICAS ANTINEOPLASTIC AGENTS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 105. AMERICAS ANTINEOPLASTIC AGENTS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 106. AMERICAS ANTINEOPLASTIC AGENTS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 107. AMERICAS ANTINEOPLASTIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 108. AMERICAS ANTINEOPLASTIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 109. AMERICAS ANTINEOPLASTIC AGENTS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 110. AMERICAS ANTINEOPLASTIC AGENTS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 111. AMERICAS ANTINEOPLASTIC AGENTS MARKET SIZE, BY HEMATOLOGICAL CANCER, 2018-2024 (USD MILLION)
TABLE 112. AMERICAS ANTINEOPLASTIC AGENTS MARKET SIZE, BY HEMATOLOGICAL CANCER, 2025-2030 (USD MILLION)
TABLE 113. AMERICAS ANTINEOPLASTIC AGENTS MARKET SIZE, BY SOLID TUMOR, 2018-2024 (USD MILLION)
TABLE 114. AMERICAS ANTINEOPLASTIC AGENTS MARKET SIZE, BY SOLID TUMOR, 2025-2030 (USD MILLION)
TABLE 115. AMERICAS ANTINEOPLASTIC AGENTS MARKET SIZE, BY LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 116. AMERICAS ANTINEOPLASTIC AGENTS MARKET SIZE, BY LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 117. AMERICAS ANTINEOPLASTIC AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 118. AMERICAS ANTINEOPLASTIC AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 119. AMERICAS ANTINEOPLASTIC AGENTS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 120. AMERICAS ANTINEOPLASTIC AGENTS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 121. UNITED STATES ANTINEOPLASTIC AGENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 122. UNITED STATES ANTINEOPLASTIC AGENTS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 123. UNITED STATES ANTINEOPLASTIC AGENTS MARKET SIZE, BY CYTOTOXIC AGENTS, 2018-2024 (USD MILLION)
TABLE 124. UNITED STATES ANTINEOPLASTIC AGENTS MARKET SIZE, BY CYTOTOXIC AGENTS, 2025-2030 (USD MILLION)
TABLE 125. UNITED STATES ANTINEOPLASTIC AGENTS MARKET SIZE, BY HORMONAL AGENTS, 2018-2024 (USD MILLION)
TABLE 126. UNITED STATES ANTINEOPLASTIC AGENTS MARKET SIZE, BY HORMONAL AGENTS, 2025-2030 (USD MILLION)
TABLE 127. UNITED STATES ANTINEOPLASTIC AGENTS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 128. UNITED STATES ANTINEOPLASTIC AGENTS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 129. UNITED STATES ANTINEOPLASTIC AGENTS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 130. UNITED STATES ANTINEOPLASTIC AGENTS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 131. UNITED STATES ANTINEOPLASTIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 132. UNITED STATES ANTINEOPLASTIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 133. UNITED STATES ANTINEOPLASTIC AGENTS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 134. UNITED STATES ANTINEOPLASTIC AGENTS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 135. UNITED STATES ANTINEOPLASTIC AGENTS MARKET SIZE, BY HEMATOLOGICAL CANCER, 2018-2024 (USD MILLION)
TABLE 136. UNITED STATES ANTINEOPLASTIC AGENTS MARKET SIZE, BY HEMATOLOGICAL CANCER, 2025-2030 (USD MILLION)
TABLE 137. UNITED STATES ANTINEOPLASTIC AGENTS MARKET SIZE, BY SOLID TUMOR, 2018-2024 (USD MILLION)
TABLE 138. UNITED STATES ANTINEOPLASTIC AGENTS MARKET SIZE, BY SOLID TUMOR, 2025-2030 (USD MILLION)
TABLE 139. UNITED STATES ANTINEOPLASTIC AGENTS MARKET SIZE, BY LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 140. UNITED STATES ANTINEOPLASTIC AGENTS MARKET SIZE, BY LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 141. UNITED STATES ANTINEOPLASTIC AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 142. UNITED STATES ANTINEOPLASTIC AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 143. UNITED STATES ANTINEOPLASTIC AGENTS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 144. UNITED STATES ANTINEOPLASTIC AGENTS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 145. CANADA ANTINEOPLASTIC AGENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 146. CANADA ANTINEOPLASTIC AGENTS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 147. CANADA ANTINEOPLASTIC AGENTS MARKET SIZE, BY CYTOTOXIC AGENTS, 2018-2024 (USD MILLION)
TABLE 148. CANADA ANTINEOPLASTIC AGENTS MARKET SIZE, BY CYTOTOXIC AGENTS, 2025-2030 (USD MILLION)
TABLE 149. CANADA ANTINEOPLASTIC AGENTS MARKET SIZE, BY HORMONAL AGENTS, 2018-2024 (USD MILLION)
TABLE 150. CANADA ANTINEOPLASTIC AGENTS MARKET SIZE, BY HORMONAL AGENTS, 2025-2030 (USD MILLION)
TABLE 151. CANADA ANTINEOPLASTIC AGENTS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 152. CANADA ANTINEOPLASTIC AGENTS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 153. CANADA ANTINEOPLASTIC AGENTS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 154. CANADA ANTINEOPLASTIC AGENTS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 155. CANADA ANTINEOPLASTIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 156. CANADA ANTINEOPLASTIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 157. CANADA ANTINEOPLASTIC AGENTS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 158. CANADA ANTINEOPLASTIC AGENTS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 159. CANADA ANTINEOPLASTIC AGENTS MARKET SIZE, BY HEMATOLOGICAL CANCER, 2018-2024 (USD MILLION)
TABLE 160. CANADA ANTINEOPLASTIC AGENTS MARKET SIZE, BY HEMATOLOGICAL CANCER, 2025-2030 (USD MILLION)
TABLE 161. CANADA ANTINEOPLASTIC AGENTS MARKET SIZE, BY SOLID TUMOR, 2018-2024 (USD MILLION)
TABLE 162. CANADA ANTINEOPLASTIC AGENTS MARKET SIZE, BY SOLID TUMOR, 2025-2030 (USD MILLION)
TABLE 163. CANADA ANTINEOPLASTIC AGENTS MARKET SIZE, BY LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 164. CANADA ANTINEOPLASTIC AGENTS MARKET SIZE, BY LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 165. CANADA ANTINEOPLASTIC AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 166. CANADA ANTINEOPLASTIC AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 167. MEXICO ANTINEOPLASTIC AGENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 168. MEXICO ANTINEOPLASTIC AGENTS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 169. MEXICO ANTINEOPLASTIC AGENTS MARKET SIZE, BY CYTOTOXIC AGENTS, 2018-2024 (USD MILLION)
TABLE 170. MEXICO ANTINEOPLASTIC AGENTS MARKET SIZE, BY CYTOTOXIC AGENTS, 2025-2030 (USD MILLION)
TABLE 171. MEXICO ANTINEOPLASTIC AGENTS MARKET SIZE, BY HORMONAL AGENTS, 2018-2024 (USD MILLION)
TABLE 172. MEXICO ANTINEOPLASTIC AGENTS MARKET SIZE, BY HORMONAL AGENTS, 2025-2030 (USD MILLION)
TABLE 173. MEXICO ANTINEOPLASTIC AGENTS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 174. MEXICO ANTINEOPLASTIC AGENTS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 175. MEXICO ANTINEOPLASTIC AGENTS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 176. MEXICO ANTINEOPLASTIC AGENTS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 177. MEXICO ANTINEOPLASTIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 178. MEXICO ANTINEOPLASTIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 179. MEXICO ANTINEOPLASTIC AGENTS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 180. MEXICO ANTINEOPLASTIC AGENTS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 181. MEXICO ANTINEOPLASTIC AGENTS MARKET SIZE, BY HEMATOLOGICAL CANCER, 2018-2024 (USD MILLION)
TABLE 182. MEXICO ANTINEOPLASTIC AGENTS MARKET SIZE, BY HEMATOLOGICAL CANCER, 2025-2030 (USD MILLION)
TABLE 183. MEXICO ANTINEOPLASTIC AGENTS MARKET SIZE, BY SOLID TUMOR, 2018-2024 (USD MILLION)
TABLE 184. MEXICO ANTINEOPLASTIC AGENTS MARKET SIZE, BY SOLID TUMOR, 2025-2030 (USD MILLION)
TABLE 185. MEXICO ANTINEOPLASTIC AGENTS MARKET SIZE, BY LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 186. MEXICO ANTINEOPLASTIC AGENTS MARKET SIZE, BY LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 187. MEXICO ANTINEOPLASTIC AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 188. MEXICO ANTINEOPLASTIC AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 189. BRAZIL ANTINEOPLASTIC AGENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 190. BRAZIL ANTINEOPLASTIC AGENTS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 191. BRAZIL ANTINEOPLASTIC AGENTS MARKET SIZE, BY CYTOTOXIC AGENTS, 2018-2024 (USD MILLION)
TABLE 192. BRAZIL ANTINEOPLASTIC AGENTS MARKET SIZE, BY CYTOTOXIC AGENTS, 2025-2030 (USD MILLION)
TABLE 193. BRAZIL ANTINEOPLASTIC AGENTS MARKET SIZE, BY HORMONAL AGENTS, 2018-2024 (USD MILLION)
TABLE 194. BRAZIL ANTINEOPLASTIC AGENTS MARKET SIZE, BY HORMONAL AGENTS, 2025-2030 (USD MILLION)
TABLE 195. BRAZIL ANTINEOPLASTIC AGENTS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 196. BRAZIL ANTINEOPLASTIC AGENTS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 197. BRAZIL ANTINEOPLASTIC AGENTS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 198. BRAZIL ANTINEOPLASTIC AGENTS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 199. BRAZIL ANTINEOPLASTIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 200. BRAZIL ANTINEOPLASTIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 201. BRAZIL ANTINEOPLASTIC AGENTS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 202. BRAZIL ANTINEOPLASTIC AGENTS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 203. BRAZIL ANTINEOPLASTIC AGENTS MARKET SIZE, BY HEMATOLOGICAL CANCER, 2018-2024 (USD MILLION)
TABLE 204. BRAZIL ANTINEOPLASTIC AGENTS MARKET SIZE, BY HEMATOLOGICAL CANCER, 2025-2030 (USD MILLION)
TABLE 205. BRAZIL ANTINEOPLASTIC AGENTS MARKET SIZE, BY SOLID TUMOR, 2018-2024 (USD MILLION)
TABLE 206. BRAZIL ANTINEOPLASTIC AGENTS MARKET SIZE, BY SOLID TUMOR, 2025-2030 (USD MILLION)
TABLE 207. BRAZIL ANTINEOPLASTIC AGENTS MARKET SIZE, BY LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 208. BRAZIL ANTINEOPLASTIC AGENTS MARKET SIZE, BY LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 209. BRAZIL ANTINEOPLASTIC AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 210. BRAZIL ANTINEOPLASTIC AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 211. ARGENTINA ANTINEOPLASTIC AGENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 212. ARGENTINA ANTINEOPLASTIC AGENTS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 213. ARGENTINA ANTINEOPLASTIC AGENTS MARKET SIZE, BY CYTOTOXIC AGENTS, 2018-2024 (USD MILLION)
TABLE 214. ARGENTINA ANTINEOPLASTIC AGENTS MARKET SIZE, BY CYTOTOXIC AGENTS, 2025-2030 (USD MILLION)
TABLE 215. ARGENTINA ANTINEOPLASTIC AGENTS MARKET SIZE, BY HORMONAL AGENTS, 2018-2024 (USD MILLION)
TABLE 216. ARGENTINA ANTINEOPLASTIC AGENTS MARKET SIZE, BY HORMONAL AGENTS, 2025-2030 (USD MILLION)
TABLE 217. ARGENTINA ANTINEOPLASTIC AGENTS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 218. ARGENTINA ANTINEOPLASTIC AGENTS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 219. ARGENTINA ANTINEOPLASTIC AGENTS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 220. ARGENTINA ANTINEOPLASTIC AGENTS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 221. ARGENTINA ANTINEOPLASTIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 222. ARGENTINA ANTINEOPLASTIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 223. ARGENTINA ANTINEOPLASTIC AGENTS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 224. ARGENTINA ANTINEOPLASTIC AGENTS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 225. ARGENTINA ANTINEOPLASTIC AGENTS MARKET SIZE, BY HEMATOLOGICAL CANCER, 2018-2024 (USD MILLION)
TABLE 226. ARGENTINA ANTINEOPLASTIC AGENTS MARKET SIZE, BY HEMATOLOGICAL CANCER, 2025-2030 (USD MILLION)
TABLE 227. ARGENTINA ANTINEOPLASTIC AGENTS MARKET SIZE, BY SOLID TUMOR, 2018-2024 (USD MILLION)
TABLE 228. ARGENTINA ANTINEOPLASTIC AGENTS MARKET SIZE, BY SOLID TUMOR, 2025-2030 (USD MILLION)
TABLE 229. ARGENTINA ANTINEOPLASTIC AGENTS MARKET SIZE, BY LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 230. ARGENTINA ANTINEOPLASTIC AGENTS MARKET SIZE, BY LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 231. ARGENTINA ANTINEOPLASTIC AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 232. ARGENTINA ANTINEOPLASTIC AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 233. EUROPE, MIDDLE EAST & AFRICA ANTINEOPLASTIC AGENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 234. EUROPE, MIDDLE EAST & AFRICA ANTINEOPLASTIC AGENTS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 235. EUROPE, MIDDLE EAST & AFRICA ANTINEOPLASTIC AGENTS MARKET SIZE, BY CYTOTOXIC AGENTS, 2018-2024 (USD MILLION)
TABLE 236. EUROPE, MIDDLE EAST & AFRICA ANTINEOPLASTIC AGENTS MARKET SIZE, BY CYTOTOXIC AGENTS, 2025-2030 (USD MILLION)
TABLE 237. EUROPE, MIDDLE EAST & AFRICA ANTINEOPLASTIC AGENTS MARKET SIZE, BY HORMONAL AGENTS, 2018-2024 (USD MILLION)
TABLE 238. EUROPE, MIDDLE EAST & AFRICA ANTINEOPLASTIC AGENTS MARKET SIZE, BY HORMONAL AGENTS, 2025-2030 (USD MILLION)
TABLE 239. EUROPE, MIDDLE EAST & AFRICA ANTINEOPLASTIC AGENTS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 240. EUROPE, MIDDLE EAST & AFRICA ANTINEOPLASTIC AGENTS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 241. EUROPE, MIDDLE EAST & AFRICA ANTINEOPLASTIC AGENTS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 242. EUROPE, MIDDLE EAST & AFRICA ANTINEOPLASTIC AGENTS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 243. EUROPE, MIDDLE EAST & AFRICA ANTINEOPLASTIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 244. EUROPE, MIDDLE EAST & AFRICA ANTINEOPLASTIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 245. EUROPE, MIDDLE EAST & AFRICA ANTINEOPLASTIC AGENTS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 246. EUROPE, MIDDLE EAST & AFRICA ANTINEOPLASTIC AGENTS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 247. EUROPE, MIDDLE EAST & AFRICA ANTINEOPLASTIC AGENTS MARKET SIZE, BY HEMATOLOGICAL CANCER, 2018-2024 (USD MILLION)
TABLE 248. EUROPE, MIDDLE EAST & AFRICA ANTINEOPLASTIC AGENTS MARKET SIZE, BY HEMATOLOGICAL CANCER, 2025-2030 (USD MILLION)
TABLE 249. EUROPE, MIDDLE EAST & AFRICA ANTINEOPLASTIC AGENTS MARKET SIZE, BY SOLID TUMOR, 2018-2024 (USD MILLION)
TABLE 250. EUROPE, MIDDLE EAST & AFRICA ANTINEOPLASTIC AGENTS MARKET SIZE, BY SOLID TUMOR, 2025-2030 (USD MILLION)
TABLE 251. EUROPE, MIDDLE EAST & AFRICA ANTINEOPLASTIC AGENTS MARKET SIZE, BY LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 252. EUROPE, MIDDLE EAST & AFRICA ANTINEOPLASTIC AGENTS MARKET SIZE, BY LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 253. EUROPE, MIDDLE EAST & AFRICA ANTINEOPLASTIC AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 254. EUROPE, MIDDLE EAST & AFRICA ANTINEOPLASTIC AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 255. EUROPE, MIDDLE EAST & AFRICA ANTINEOPLASTIC AGENTS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 256. EUROPE, MIDDLE EAST & AFRICA ANTINEOPLASTIC AGENTS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 257. UNITED KINGDOM ANTINEOPLASTIC AGENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 258. UNITED KINGDOM ANTINEOPLASTIC AGENTS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 259. UNITED KINGDOM ANTINEOPLASTIC AGENTS MARKET SIZE, BY CYTOTOXIC AGENTS, 2018-2024 (USD MILLION)
TABLE 260. UNITED KINGDOM ANTINEOPLASTIC AGENTS MARKET SIZE, BY CYTOTOXIC AGENTS, 2025-2030 (USD MILLION)
TABLE 261. UNITED KINGDOM ANTINEOPLASTIC AGENTS MARKET SIZE, BY HORMONAL AGENTS, 2018-2024 (USD MILLION)
TABLE 262. UNITED KINGDOM ANTINEOPLASTIC AGENTS MARKET SIZE, BY HORMONAL AGENTS, 2025-2030 (USD MILLION)
TABLE 263. UNITED KINGDOM ANTINEOPLASTIC AGENTS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 264. UNITED KINGDOM ANTINEOPLASTIC AGENTS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 265. UNITED KINGDOM ANTINEOPLASTIC AGENTS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 266. UNITED KINGDOM ANTINEOPLASTIC AGENTS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 267. UNITED KINGDOM ANTINEOPLASTIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 268. UNITED KINGDOM ANTINEOPLASTIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 269. UNITED KINGDOM ANTINEOPLASTIC AGENTS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 270. UNITED KINGDOM ANTINEOPLASTIC AGENTS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 271. UNITED KINGDOM ANTINEOPLASTIC AGENTS MARKET SIZE, BY HEMATOLOGICAL CANCER, 2018-2024 (USD MILLION)
TABLE 272. UNITED KINGDOM ANTINEOPLASTIC AGENTS MARKET SIZE, BY HEMATOLOGICAL CANCER, 2025-2030 (USD MILLION)
TABLE 273. UNITED KINGDOM ANTINEOPLASTIC AGENTS MARKET SIZE, BY SOLID TUMOR, 2018-2024 (USD MILLION)
TABLE 274. UNITED KINGDOM ANTINEOPLASTIC AGENTS MARKET SIZE, BY SOLID TUMOR, 2025-2030 (USD MILLION)
TABLE 275. UNITED KINGDOM ANTINEOPLASTIC AGENTS MARKET SIZE, BY LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 276. UNITED KINGDOM ANTINEOPLASTIC AGENTS MARKET SIZE, BY LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 277. UNITED KINGDOM ANTINEOPLASTIC AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 278. UNITED KINGDOM ANTINEOPLASTIC AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 279. GERMANY ANTINEOPLASTIC AGENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 280. GERMANY ANTINEOPLASTIC AGENTS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 281. GERMANY ANTINEOPLASTIC AGENTS MARKET SIZE, BY CYTOTOXIC AGENTS, 2018-2024 (USD MILLION)
TABLE 282. GERMANY ANTINEOPLASTIC AGENTS MARKET SIZE, BY CYTOTOXIC AGENTS, 2025-2030 (USD MILLION)
TABLE 283. GERMANY ANTINEOPLASTIC AGENTS MARKET SIZE, BY HORMONAL AGENTS, 2018-2024 (USD MILLION)
TABLE 284. GERMANY ANTINEOPLASTIC AGENTS MARKET SIZE, BY HORMONAL AGENTS, 2025-2030 (USD MILLION)
TABLE 285. GERMANY ANTINEOPLASTIC AGENTS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 286. GERMANY ANTINEOPLASTIC AGENTS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 287. GERMANY ANTINEOPLASTIC AGENTS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 288. GERMANY ANTINEOPLASTIC AGENTS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 289. GERMANY ANTINEOPLASTIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 290. GERMANY ANTINEOPLASTIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 291. GERMANY ANTINEOPLASTIC AGENTS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 292. GERMANY ANTINEOPLASTIC AGENTS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 293. GERMANY ANTINEOPLASTIC AGENTS MARKET SIZE, BY HEMATOLOGICAL CANCER, 2018-2024 (USD MILLION)
TABLE 294. GERMANY ANTINEOPLASTIC AGENTS MARKET SIZE, BY HEMATOLOGICAL CANCER, 2025-2030 (USD MILLION)
TABLE 295. GERMANY ANTINEOPLASTIC AGENTS MARKET SIZE, BY SOLID TUMOR, 2018-2024 (USD MILLION)
TABLE 296. GERMANY ANTINEOPLASTIC AGENTS MARKET SIZE, BY SOLID TUMOR, 2025-2030 (USD MILLION)
TABLE 297. GERMANY ANTINEOPLASTIC AGENTS MARKET SIZE, BY LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 298. GERMANY ANTINEOPLASTIC AGENTS MARKET SIZE, BY LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 299. GERMANY ANTINEOPLASTIC AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 300. GERMANY ANTINEOPLASTIC AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 301. FRANCE ANTINEOPLASTIC AGENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 302. FRANCE ANTINEOPLASTIC AGENTS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 303. FRANCE ANTINEOPLASTIC AGENTS MARKET SIZE, BY CYTOTOXIC AGENTS, 2018-2024 (USD MILLION)
TABLE 304. FRANCE ANTINEOPLASTIC AGENTS MARKET SIZE, BY CYTOTOXIC AGENTS, 2025-2030 (USD MILLION)
TABLE 305. FRANCE ANTINEOPLASTIC AGENTS MARKET SIZE, BY HORMONAL AGENTS, 2018-2024 (USD MILLION)
TABLE 306. FRANCE ANTINEOPLASTIC AGENTS MARKET SIZE, BY HORMONAL AGENTS, 2025-2030 (USD MILLION)
TABLE 307. FRANCE ANTINEOPLASTIC AGENTS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 308. FRANCE ANTINEOPLASTIC AGENTS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 309. FRANCE ANTINEOPLASTIC AGENTS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 310. FRANCE ANTINEOPLASTIC AGENTS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 311. FRANCE ANTINEOPLASTIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 312. FRANCE ANTINEOPLASTIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 313. FRANCE ANTINEOPLASTIC AGENTS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 314. FRANCE ANTINEOPLASTIC AGENTS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 315. FRANCE ANTINEOPLASTIC AGENTS MARKET SIZE, BY HEMATOLOGICAL CANCER, 2018-2024 (USD MILLION)
TABLE 316. FRANCE ANTINEOPLASTIC AGENTS MARKET SIZE, BY HEMATOLOGICAL CANCER, 2025-2030 (USD MILLION)
TABLE 317. FRANCE ANTINEOPLASTIC AGENTS MARKET SIZE, BY SOLID TUMOR, 2018-2024 (USD MILLION)
TABLE 318. FRANCE ANTINEOPLASTIC AGENTS MARKET SIZE, BY SOLID TUMOR, 2025-2

Samples

Loading
LOADING...

Companies Mentioned

The major companies profiled in this Antineoplastic Agents market report include:
  • Roche Holding AG
  • Merck & Co., Inc.
  • Johnson & Johnson
  • Bristol-Myers Squibb Company
  • Novartis AG
  • Pfizer Inc.
  • AstraZeneca PLC
  • AbbVie Inc.
  • Amgen Inc.
  • Eli Lilly and Company

Table Information

Report AttributeDetails
No. of Pages199
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 158.96 Billion
Forecasted Market Value ( USD ) by 2030 $ 260.98 Billion
Compound Annual Growth Rate10.4%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Antineoplastic Agents - Global Strategic Business Report - Product Image

Antineoplastic Agents - Global Strategic Business Report

  • Report
  • 183 Pages
  • Global
From
Taxane Antineoplastic Drug Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application, Product Type - Product Image

Taxane Antineoplastic Drug Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application, Product Type

  • Report
  • 115 Pages
  • Global
From
Anti-Neoplastic Agents Market Report 2025 - Product Image

Anti-Neoplastic Agents Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Cytotoxic Drugs - Global Strategic Business Report - Product Image

Cytotoxic Drugs - Global Strategic Business Report

  • Report
  • 462 Pages
  • Global
From
Anti-Tumor Drugs Market by Drug Class (Chemotherapy, Hormonal Therapy, Immunotherapy), Molecule Type (Monoclonal Antibody, Nucleic Acid, Peptide), Indication, Route Of Administration, Therapy Line, Distribution Channel, End User, Patient Age Group - Global Forecast 2025-2030 - Product Image

Anti-Tumor Drugs Market by Drug Class (Chemotherapy, Hormonal Therapy, Immunotherapy), Molecule Type (Monoclonal Antibody, Nucleic Acid, Peptide), Indication, Route Of Administration, Therapy Line, Distribution Channel, End User, Patient Age Group - Global Forecast 2025-2030

  • Report
  • 181 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.